Category: Behind the Science
New frontiers in inflammasome therapeutics
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
What the market overlooked in Seelos’s recent trehalose study
Atuka’s Jonathan Brotchie and Patrick Howson take a deeper look at the top-line results for IV trehalose, an ALS treatment, and see signs of potential for the compound that the market may have missed.
Tavapodon offers great promise as a new therapeutic for Parkinson’s disease
On the encouraging topline results from Cerevel Therapeutics’ Phase III TEMPO-3 trial for tavapadon, a D1/D5 dopamine receptor partial agonist.
